$ABSI

Szela Mary T purchased 12,900 shares of Absci Corp (ABSI) at $11.54 ($0.15M total) on 2026-06-30.

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

Absci Corp (ABSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d139233dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ABSCI CORPORATION 13,495,277 Shares of Common Stock Underwriting Agreement June 24, 2026 Jefferies LLC J.P. Morgan Securities LLC TD Securities (USA) LLC Guggenheim Securities, LLC As Representatives of the sev

Absci (NASDAQ:ABSI) shares rose 11% on Friday, despite missing quarterly earnings and revenue expectations significantly. The company operates with a negative net margin and analysts forecast a negative EPS for the fiscal year, leading to a consensus "Hold" rating with an average price target of $6.44. Insider ownership is 10.49% (including a recent purchase by Andreas Busch) and institutional ownership is approximately 52%.

Several prominent stocks are projected to open lower in Wednesday's pre-market session. Absci Corp (NASDAQ: ABSI) is down after reporting lower-than-expected quarterly sales, while DigitalOcean Holdings Inc (NYSE: DOCN) declined following a $700 million offering announcement. Other companies experiencing pre-market dips include Intrepid Potash Inc (NYSE: IPI), Pacira Biosciences Inc (NASDAQ: PCRX), Velo3D Inc (NASDAQ: VELO), Sasol Ltd (NYSE: SSL), CF Industries Holdings, Inc. (NYSE: CF), and Venture Global Inc (NASDAQ: VG).

Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for therapeutic development, announced its participation in four upcoming investor conferences in March 2026. The company will engage in fireside chats and host one-on-one meetings with investors at events including the TD Cowen 46th Annual Health Care Conference and Leerink Partners 2026 Global Healthcare Conference. Webcasts of the fireside chats will be available on Absci's investor relations website.

Absci Corp presented a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company highlighted its generative AI platform for drug creation and discussed promising preclinical results for ABS-201, which targets androgenetic alopecia. Phase 1/2a trials for ABS-201 in both AGA and endometriosis are currently underway, with the drug aiming to redefine treatment categories due to its novel mechanisms and significant market potential.

Absci Corporation (NASDAQ: ABSI) has garnered a full buy consensus among analysts, with a median price target suggesting a 150.70% upside potential. H.C. Wainwright recently reaffirmed a 'Buy' rating and raised the price target to $8, citing the incorporation of ABS-201, an AI-designed antibody for androgenetic alopecia, into the company's model. Preclinical data indicates ABS-201's strong potential to stimulate hair growth and regenerate stem cells.

Absci Corporation has announced a partnership with U.S. soccer legend Landon Donovan to raise awareness about the emotional impact of androgenetic alopecia (AGA) and the need for better therapeutic options. Donovan, who will share his personal hair loss journey at an upcoming Key Opinion Leader seminar, aims to destigmatize the condition and support Absci's scientific approach to developing treatments. Absci's investigational antibody, ABS-201, designed with generative AI, targets prolactin receptors for hair follicle regeneration and is expected to have interim data from its Phase 1/2a HEADLINE study in the second half of 2026.

Image source: The Motley Fool.Wednesday, November 12, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...